SCHEMBL25377342

SCHEMBL25377342

Cn1ccc(-c2cc(-c3ccc(F)cc3)ccc2Cl)n1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SCN4A P35499 1/20 0.51
▸ KCNH2 Q12809 6/20 0.41
▸ KEAP1 Q14145 1/20 0.40
▸ MAPK13 O15264 1/20 0.39
▸ CSNK1D P48730 1/20 0.39
▸ CSNK1E P49674 1/20 0.39
▸ MAPK12 P53778 1/20 0.39
▸ MAPK11 Q15759 1/20 0.39
▸ MAPK14 Q16539 1/20 0.39
▸ KMT2A Q03164 1/20 0.39
▸ MAP4K4 O95819 1/20 0.38
▸ EGFR P00533 1/20 0.38
▸ FRK P42685 1/20 0.38
▸ MAPK9 P45984 1/20 0.38
▸ CSNK1A1 P48729 1/20 0.38
▸ CASP6 P55212 1/20 0.37
▸ DRD2 P14416 1/20 0.37
▸ ADORA2A P29274 1/20 0.36
▸ NTRK1 P04629 2/20 0.36
▸ PPP1CA P62136 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26192909 0.82 SCN4A (0.51) SCN4AKCNH2KEAP1MAPK13CSNK1D
SCHEMBL25262340 0.81 SCN4A (0.48) SCN4AKEAP1MAPK13CSNK1DCSNK1E
SCHEMBL26199143 0.78 SCN4A (0.48) SCN4AKEAP1CSNK1DCSNK1EKMT2A
SCHEMBL30510115 0.78 SCN4A (0.54) SCN4AKCNH2KEAP1MAPK13CSNK1D
SCHEMBL25258292 0.78 SCN4A (0.54) SCN4AKCNH2KEAP1MAPK13CSNK1D
SCHEMBL26192910 0.76 SCN4A (0.46) SCN4AKEAP1MAPK13CSNK1DCSNK1E
SCHEMBL989300 0.76 SCN4A (0.79) SCN4AKEAP1MAPK13CSNK1DCSNK1E
Hydrochloric Acid SCHEMBL25377933 0.74 SCN4A (0.44) SCN4AKEAP1KMT2ACASP6DRD2
SCHEMBL25833013 0.72 SCN4A (0.45) SCN4AKEAP1MAP4K4CASP6NTRK1
SCHEMBL25833010 0.72 SCN4A (0.45) SCN4AKEAP1CASP6ADORA2ANTRK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12552772-B2 2-pyrazole anilines and related analogs for inhibiting YAP/TAZ-TEAD SPRINGWORKS THERAPEUTICS, INC. (US) 2026-02-17 — — US disclosed
US-20250115574-A1 2-PYRAZOLE ANILINES AND RELATED ANALOGS FOR INHIBITING YAP/TAZ-TEAD VIB VZW (BE) 2025-04-10 — — US disclosed
EP-4452253-A2 2-PYRAZOLE ANILINES AND RELATED ANALOGS FOR INHIBITING YAP/TAZ-TEAD The Katholieke Universiteit Leuven (BE) 2024-10-30 — — EP disclosed
US-12030866-B2 2-pyrazole anilines and related analogs for inhibiting YAP/TAZ-TEAD SPRINGWORKS THERAPEUTICS, INC. (US) 2024-07-09 — — US disclosed
US-12030866-B2 2-pyrazole anilines and related analogs for inhibiting YAP/TAZ-TEAD SPRINGWORKS THERAPEUTICS, INC. (US) 2024-07-09 — — US disclosed
US-12030866-B2 2-pyrazole anilines and related analogs for inhibiting YAP/TAZ-TEAD SPRINGWORKS THERAPEUTICS, INC. (US) 2024-07-09 — — US disclosed
WO-2023122780-A9 2-PYRAZOLE ANILINES AND RELATED ANALOGS FOR INHIBITING YAP/TAZ-TEAD THE KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2023-11-30 — — WO disclosed
WO-2023122780-A9 2-PYRAZOLE ANILINES AND RELATED ANALOGS FOR INHIBITING YAP/TAZ-TEAD THE KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2023-11-30 — — WO disclosed
US-20230278982-A1 2-Pyrazole Anilines and Related Analogs for Inhibiting YAP/TAZ-TEAD KU LEUVEN R&D (BE) 2023-09-07 — — US disclosed
US-20230278982-A1 2-Pyrazole Anilines and Related Analogs for Inhibiting YAP/TAZ-TEAD KU LEUVEN R&D (BE) 2023-09-07 — — US disclosed
US-20230278982-A1 2-Pyrazole Anilines and Related Analogs for Inhibiting YAP/TAZ-TEAD KU LEUVEN R&D (BE) 2023-09-07 — — US disclosed
WO-2023122780-A2 2-PYRAZOLE ANILINES AND RELATED ANALOGS FOR INHIBITING YAP/TAZ-TEAD THE KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2023-06-29 — — WO disclosed
WO-2023122780-A2 2-PYRAZOLE ANILINES AND RELATED ANALOGS FOR INHIBITING YAP/TAZ-TEAD THE KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2023-06-29 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12552772-B2 2-pyrazole anilines and related analogs for inhibiting YAP/TAZ-TEAD YAP1, TEAD3, TEAD2 SCN4A 3592/4885KCNH2 4520/4885KEAP1 303/4885
US-20230278982-A1 2-Pyrazole Anilines and Related Analogs for Inhibiting YAP/TAZ-TEAD YAP1, TEAD3, TEAD2 SCN4A 4415/4885KCNH2 4789/4885KEAP1 202/4885
US-12030866-B2 2-pyrazole anilines and related analogs for inhibiting YAP/TAZ-TEAD YAP1, TEAD3, TEAD2 SCN4A 4415/4885KCNH2 4789/4885KEAP1 202/4885
US-20250115574-A1 2-PYRAZOLE ANILINES AND RELATED ANALOGS FOR INHIBITING YAP/TAZ-TEAD YAP1, TEAD3, TEAD2 SCN4A 4415/4885KCNH2 4789/4885KEAP1 202/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback